Loading organizations...
§ Private Profile · Devonshire House. Manor Way. Borehamwood, Hertfordshire WD6 1QQ, UK.
Medial is a technology company.
Medial operates a specialized professional social networking platform tailored for the dynamic Indian startup ecosystem. The company’s core product facilitates connections among founders, investors, and talent, offering a dedicated space for industry news, job opportunities, and startup insights. This platform differentiates itself by focusing on the unique needs and rapid developments within the startup community, providing a centralized hub for engagement and information exchange.
The company was co-founded in 2023 by Niket Raj Dwivedi, Prateek Kaien, Harsh Dwivedi, and Aishwarya Raj. Their collective insight recognized a gap in the market for a professional social network specifically designed to foster growth and collaboration within the burgeoning Indian startup landscape. The founders aimed to build a community-driven platform that transcends general professional networking sites, providing targeted resources and interactions.
Medial serves a diverse user base, including aspiring entrepreneurs, seasoned founders, venture capitalists, business analysts, and various professionals engaged in the startup sector. The company’s vision is to become the definitive resource and networking destination for the Indian startup ecosystem, enabling its members to navigate challenges, discover opportunities, and contribute to the collective advancement of innovation.
Medial has raised $620K across 2 funding rounds.
Medial has raised $620K in total across 2 funding rounds.
Medial has raised $620K across 2 funding rounds. Most recently, it raised $500K Seed in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $500K Seed | — | Prime Venture Partners | Announced |
| Jan 18, 2024 | $120K Pre Seed | First Cheque | Ankit Aggarwal, Nayan Jadeja, Radhakrishnan Ramachandran, Rohitashwa Choudhary | Announced |
Medial has raised $620K in total across 2 funding rounds.
Medial's investors include Prime Venture Partners, First Cheque, Ankit Aggarwal, Nayan Jadeja, Radhakrishnan Ramachandran, Rohitashwa Choudhary.
No company named Medial appears in current records as a prominent technology company, investment firm, or medical technology (medtech) player. Search results highlight leading medtech firms like GE HealthCare, which spun off from GE in January 2023 and reported $19.6 billion in 2023 revenues from imaging, ultrasound, and AI-powered innovations serving hospitals and clinicians globally[1][2]. Similarly, Stryker impacts over 150 million patients annually through orthopaedics, neurotechnology, and medical devices, with recent expansions like the InThrill Thrombectomy System[6]. These firms address healthcare efficiency, patient outcomes, and precision care in a market projected to grow from $518 billion in 2023 to $886 billion by 2030[1].
Medtech companies generally develop devices (e.g., MRI machines, pacemakers), software (e.g., EHRs, telemedicine), and diagnostics to solve clinical challenges, serving providers, patients, and biopharma amid rising demand for remote monitoring and AI integration[3][8]. If "Medial" refers to a specific startup or lesser-known entity, details are absent from available sources; it may be a misspelling or emerging player without public traction.
Without specific data on Medial, its backstory remains unclear from searches. For context, GE HealthCare originated from GE's 2021 demerger announcement, completing as a standalone entity in 2023 with a focus on supply chain improvements and AI innovations under CEO Roy Jakobs[1][2]. Stryker has evolved as a global medtech leader, recently appointing Spencer Stiles as COO effective January 2026 to drive strategy and M&A[6]. Broader medtech giants like these trace roots to heavy R&D investments, innovating from early devices to today's integrated solutions[3][8].
Medtech as an industry supports 2 million U.S. jobs, with firms prioritizing innovation over other sectors, often starting from subsectors like electro-medical equipment (e.g., pacemakers, MRIs)[8].
Medial lacks documented differentiators; it does not match profiles of top firms in revenue, products, or track record[1][5][7][9].
Medial plays no identifiable role in tech or medtech ecosystems per available data. The sector rides trends like AI diagnostics, telemedicine post-COVID, and precision therapies, fueled by macro demand and easing constraints[1][3]. U.S. medtech's high R&D spend drives global competitiveness, supporting 500,000+ direct jobs and innovations in imaging, irradiation, and monitoring[8]. Timing favors growth via collaborations (e.g., Stryker-Inari Medical), influencing efficiency in aging populations and chronic care[6]. Market forces like biopharma partnerships amplify impact[4].
Absent verifiable info, Medial's trajectory is unknown—likely not a major player amid dominators like GE HealthCare eyeing 2024 improvements and Stryker's 2026 leadership shift[1][6]. Trends shaping medtech include AI integration, cell/gene therapy logistics, and community oncology innovation, positioning established firms for $886B market capture by 2030[1][4]. If Medial emerges, success hinges on unique tech in high-growth areas like remote care; otherwise, it fades against giants redefining healthcare limits[2]. Clarify the query for targeted insights on similar entities.